Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q16620

UPID:
NTRK2_HUMAN

ALTERNATIVE NAMES:
GP145-TrkB; Neurotrophic tyrosine kinase receptor type 2; TrkB tyrosine kinase; Tropomyosin-related kinase B

ALTERNATIVE UPACC:
Q16620; B1ANZ4; B4DFV9; Q16675; Q59GJ1; Q8WXJ5; Q8WXJ6; Q8WXJ7

BACKGROUND:
TrkB tyrosine kinase, or GP145-TrkB, is a receptor tyrosine kinase essential for neuron survival and cognitive functions. It acts as a receptor for BDNF and NTF4, promoting neuron survival, differentiation, and synaptic plasticity. TrkB's activation triggers multiple signaling pathways, including the GRB2-Ras-MAPK and Ras-PI3 kinase-AKT1 cascades, which are crucial for neuronal differentiation and survival, and the PLCG1 pathway, which is vital for synaptic plasticity and learning.

THERAPEUTIC SIGNIFICANCE:
Involvement of TrkB in severe neurological disorders such as Developmental and epileptic encephalopathy 58 and conditions marked by obesity and developmental delays underscores its therapeutic significance. Targeting TrkB signaling pathways offers a promising avenue for developing treatments for these debilitating diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.